Cargando…
The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study
INTRODUCTION: Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and associated antibiotics), and the effectiveness an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912999/ https://www.ncbi.nlm.nih.gov/pubmed/36763243 http://dx.doi.org/10.1007/s40121-023-00762-9 |
_version_ | 1784885321564946432 |
---|---|
author | Soriano, Alex Montravers, Philippe Bassetti, Matteo Klyasova, Galina Daikos, George Irani, Paurus Stone, Gregory Chambers, Richard Peeters, Pascale Shah, Mitesh Hulin, Claire Albuquerque, Natalia Basin, Efim Gaborit, Benjamin Kourbeti, Irene Menichetti, Francesco Perez-Rodriguez, María Teresa Pletz, Mathias W. Sanchez, Marisa Trompa, Ivan Verma, Anita de Figueiredo, Maria Lavinea N. Charbonneau, Claudie |
author_facet | Soriano, Alex Montravers, Philippe Bassetti, Matteo Klyasova, Galina Daikos, George Irani, Paurus Stone, Gregory Chambers, Richard Peeters, Pascale Shah, Mitesh Hulin, Claire Albuquerque, Natalia Basin, Efim Gaborit, Benjamin Kourbeti, Irene Menichetti, Francesco Perez-Rodriguez, María Teresa Pletz, Mathias W. Sanchez, Marisa Trompa, Ivan Verma, Anita de Figueiredo, Maria Lavinea N. Charbonneau, Claudie |
author_sort | Soriano, Alex |
collection | PubMed |
description | INTRODUCTION: Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and associated antibiotics), and the effectiveness and safety of ceftazidime–avibactam in real-world clinical practice. METHODS: This non-interventional medical chart review study was conducted in 11 countries across the European and Latin American (LATAM) regions. Consecutive patients treated in clinical practice with at least one dose of ceftazidime–avibactam for an approved indication per country label since 01 January 2018 (or launch date in the country if posterior) were enrolled. Effectiveness analyses were conducted in patients treated with ceftazidime–avibactam for at least 72 h. RESULTS: Of the 569 eligible patients enrolled, 516 (90.7%) were treated for at least 72 h (354 patients from Europe and 162 patients from LATAM); 390 patients (75.7%) had switched from another antibiotic line for Gram-negative coverage. Infection sources were intra-abdominal, urinary, respiratory, bloodstream infections, and other infections (approximately 20% each). K. pneumoniae was the most common microorganism identified in the latest microbiological evaluation before starting ceftazidime–avibactam (59.3%). Two-thirds of microorganisms tested for susceptibility were MDR, of which 89.3% were carbapenem-resistant. The common MDR mechanisms for K. pneumoniae were carbapenemase (33.9%), oxacillinase 48 (25.2%), extended-spectrum beta-lactamase (21.5%), or metallo-beta-lactamase (14.2%) production. Without prior patient exposure, 17 isolates (mostly K. pneumoniae) were resistant to ceftazidime–avibactam. Treatment success was achieved in 77.3% of patients overall (88.3% among patients with urinary infection), regardless of first or second treatment line. In-hospital mortality rate was 23.1%. Adverse events were reported for six of the 569 patients enrolled. CONCLUSION: This study provides important real-world evidence on treatment patterns, effectiveness, and safety of ceftazidime–avibactam in clinical practice through its recruitment in the European and LATAM regions. Ceftazidime–avibactam is one of the antibiotics to consider for treatment of MDR bacteria. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03923426. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-023-00762-9. |
format | Online Article Text |
id | pubmed-9912999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-99129992023-02-13 The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study Soriano, Alex Montravers, Philippe Bassetti, Matteo Klyasova, Galina Daikos, George Irani, Paurus Stone, Gregory Chambers, Richard Peeters, Pascale Shah, Mitesh Hulin, Claire Albuquerque, Natalia Basin, Efim Gaborit, Benjamin Kourbeti, Irene Menichetti, Francesco Perez-Rodriguez, María Teresa Pletz, Mathias W. Sanchez, Marisa Trompa, Ivan Verma, Anita de Figueiredo, Maria Lavinea N. Charbonneau, Claudie Infect Dis Ther Original Research INTRODUCTION: Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and associated antibiotics), and the effectiveness and safety of ceftazidime–avibactam in real-world clinical practice. METHODS: This non-interventional medical chart review study was conducted in 11 countries across the European and Latin American (LATAM) regions. Consecutive patients treated in clinical practice with at least one dose of ceftazidime–avibactam for an approved indication per country label since 01 January 2018 (or launch date in the country if posterior) were enrolled. Effectiveness analyses were conducted in patients treated with ceftazidime–avibactam for at least 72 h. RESULTS: Of the 569 eligible patients enrolled, 516 (90.7%) were treated for at least 72 h (354 patients from Europe and 162 patients from LATAM); 390 patients (75.7%) had switched from another antibiotic line for Gram-negative coverage. Infection sources were intra-abdominal, urinary, respiratory, bloodstream infections, and other infections (approximately 20% each). K. pneumoniae was the most common microorganism identified in the latest microbiological evaluation before starting ceftazidime–avibactam (59.3%). Two-thirds of microorganisms tested for susceptibility were MDR, of which 89.3% were carbapenem-resistant. The common MDR mechanisms for K. pneumoniae were carbapenemase (33.9%), oxacillinase 48 (25.2%), extended-spectrum beta-lactamase (21.5%), or metallo-beta-lactamase (14.2%) production. Without prior patient exposure, 17 isolates (mostly K. pneumoniae) were resistant to ceftazidime–avibactam. Treatment success was achieved in 77.3% of patients overall (88.3% among patients with urinary infection), regardless of first or second treatment line. In-hospital mortality rate was 23.1%. Adverse events were reported for six of the 569 patients enrolled. CONCLUSION: This study provides important real-world evidence on treatment patterns, effectiveness, and safety of ceftazidime–avibactam in clinical practice through its recruitment in the European and LATAM regions. Ceftazidime–avibactam is one of the antibiotics to consider for treatment of MDR bacteria. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03923426. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-023-00762-9. Springer Healthcare 2023-02-10 2023-03 /pmc/articles/PMC9912999/ /pubmed/36763243 http://dx.doi.org/10.1007/s40121-023-00762-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Soriano, Alex Montravers, Philippe Bassetti, Matteo Klyasova, Galina Daikos, George Irani, Paurus Stone, Gregory Chambers, Richard Peeters, Pascale Shah, Mitesh Hulin, Claire Albuquerque, Natalia Basin, Efim Gaborit, Benjamin Kourbeti, Irene Menichetti, Francesco Perez-Rodriguez, María Teresa Pletz, Mathias W. Sanchez, Marisa Trompa, Ivan Verma, Anita de Figueiredo, Maria Lavinea N. Charbonneau, Claudie The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study |
title | The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study |
title_full | The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study |
title_fullStr | The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study |
title_full_unstemmed | The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study |
title_short | The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study |
title_sort | use and effectiveness of ceftazidime–avibactam in real-world clinical practice: ezteam study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912999/ https://www.ncbi.nlm.nih.gov/pubmed/36763243 http://dx.doi.org/10.1007/s40121-023-00762-9 |
work_keys_str_mv | AT sorianoalex theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT montraversphilippe theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT bassettimatteo theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT klyasovagalina theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT daikosgeorge theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT iranipaurus theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT stonegregory theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT chambersrichard theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT peeterspascale theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT shahmitesh theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT hulinclaire theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT albuquerquenatalia theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT basinefim theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT gaboritbenjamin theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT kourbetiirene theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT menichettifrancesco theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT perezrodriguezmariateresa theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT pletzmathiasw theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT sanchezmarisa theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT trompaivan theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT vermaanita theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT defigueiredomarialavinean theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT charbonneauclaudie theuseandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT sorianoalex useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT montraversphilippe useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT bassettimatteo useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT klyasovagalina useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT daikosgeorge useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT iranipaurus useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT stonegregory useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT chambersrichard useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT peeterspascale useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT shahmitesh useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT hulinclaire useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT albuquerquenatalia useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT basinefim useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT gaboritbenjamin useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT kourbetiirene useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT menichettifrancesco useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT perezrodriguezmariateresa useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT pletzmathiasw useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT sanchezmarisa useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT trompaivan useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT vermaanita useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT defigueiredomarialavinean useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy AT charbonneauclaudie useandeffectivenessofceftazidimeavibactaminrealworldclinicalpracticeezteamstudy |